Antibody data
- Antibody Data
- Antigen structure
- References [141]
- Comments [0]
- Validations
- Western blot [4]
- Immunohistochemistry [2]
- Flow cytometry [3]
- Other assay [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-14057 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ErbB2 (HER-2) Antibody Cocktail
- Antibody type
- Monoclonal
- Antigen
- Synthetic peptide
- Description
- MA5-14057 targets HER-2 in IHC (P), IP, ICC/IF, FACS and WB applications and shows reactivity with Human samples.
- Antibody clone number
- e2-4001, 3B5
- Concentration
- 150 µg/mL
Submitted references Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic Pheochromocytoma and Paraganglioma.
Repurposing of KLF5 activates a cell cycle signature during the progression from a precursor state to oesophageal adenocarcinoma.
Helicobacter pylori infection impairs chaperone-assisted maturation of Na-K-ATPase in gastric epithelium.
Proteomic Profile of Sorafenib Resistance in Hepatocellular Carcinoma; GRP78 Expression Is Associated With Inferior Response to Sorafenib.
Differential effect of parity on rat mammary carcinogenesis after pre- or post-pubertal exposure to radiation.
Robust Bayesian Fluorescence Lifetime Estimation, Decay Model Selection and Instrument Response Determination for Low-Intensity FLIM Imaging.
Activating ERBB4 mutations in non-small cell lung cancer.
Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma.
HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.
A genetic basis for the variation in the vulnerability of cancer to DNA damage.
Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells.
Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.
Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.
Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine.
The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines.
Molecular architecture of the ErbB2 extracellular domain homodimer.
Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas.
Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers.
HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.
Neuregulin-1/glial growth factor stimulates Schwann cell migration by inducing α5 β1 integrin-ErbB2-focal adhesion kinase complex formation.
Hormone receptors and age distribution in breast cancer patients at a university hospital in northern egypt.
A cell-based screening system for influenza A viral RNA transcription/replication inhibitors.
Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.
Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma.
Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
Association of human epidermal growth factor receptor-2 expression and clinicopathological findings in patients with colorectal cancer.
Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes.
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.
Clinicopathologic features of the mixed epithelial and mesenchymal type metaplastic breast carcinoma with myoepithelial differentiation in a subset of six cases.
EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway.
Prognostic value of oncoprotein expressions in thyroid papillary carcinoma.
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs.
Early changes in carcinogenesis of colorectal adenomas.
Early changes in carcinogenesis of colorectal adenomas.
C-Erb-b2 oncogene expression in intraductal proliferative lesions of the breast.
Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype.
ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells.
Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model.
An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch.
HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.
Invasive lobular carcinoma with extracellular mucin as a distinct variant of lobular carcinoma: a case report.
Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome.
A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters.
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression.
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.
Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.
Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity.
HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2/neu)-targeted immunotoxin with a replication-competent adenovirus or etoposide.
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.
Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery.
Immunohistochemical characterization of subtypes of male breast carcinoma.
HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats.
Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.
Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice.
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.
Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.
Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression.
Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent.
Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.
Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation.
Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes.
Lipid raft localization of ErbB2 in vestibular schwannoma and schwann cells.
Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer.
Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Loss of annexin A1 expression in breast cancer progression.
A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents.
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF.
Primary neuroendocrine carcinoma of the breast: a case report.
Primary neuroendocrine carcinoma of the breast: a case report.
Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.
The ErbB4 receptor in fetal rat lung fibroblasts and epithelial type II cells.
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
ErbB4 regulates fetal surfactant phospholipid synthesis in primary fetal rat type II cells.
Abundance and localization of skeletal muscle-related erbB2 may stimulate tumour growth during initial stages of oral oncogenesis.
[An analysis of genetic transmission in a father and son with osteosarcoma].
MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC).
Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way.
ErbB receptor dimerization, localization, and co-localization in mouse lung type II epithelial cells.
Clonal nature of sclerosing polycystic adenosis of salivary glands demonstrated by using the polymorphism of the human androgen receptor (HUMARA) locus as a marker.
Clonal nature of sclerosing polycystic adenosis of salivary glands demonstrated by using the polymorphism of the human androgen receptor (HUMARA) locus as a marker.
Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation.
Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.
The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer.
Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells.
Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer.
CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
Cystic hypersecretory carcinoma: rare and poorly recognized variant of intraductal carcinoma of the breast. Report of five cases.
Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry.
Concordant loss of fragile gene expression early in breast cancer development.
Effect of N-cadherin misexpression by the mammary epithelium in mice.
Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy.
Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK.
Ductal carcinoma in situ with spindle cells: a potential diagnostic pitfall in the evaluation of breast lesions.
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients.
Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients.
Role of ErbB2 in Corneal Epithelial Wound Healing.
Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.
Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells.
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.
Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells.
Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease.
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer.
Classification of low-grade neuroendocrine tumors of midgut and unknown origin.
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Differential cytoskeletal association of ErbB1 and ErbB2 during keratinocyte differentiation.
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Wang Y, Chen D, Pang Y, Xu X, Guan X, Liu L
Frontiers in endocrinology 2022;13:882906
Frontiers in endocrinology 2022;13:882906
Repurposing of KLF5 activates a cell cycle signature during the progression from a precursor state to oesophageal adenocarcinoma.
Rogerson C, Ogden S, Britton E, OCCAMS Consortium, Ang Y, Sharrocks AD
eLife 2020 Sep 3;9
eLife 2020 Sep 3;9
Helicobacter pylori infection impairs chaperone-assisted maturation of Na-K-ATPase in gastric epithelium.
Marcus EA, Tokhtaeva E, Jimenez JL, Wen Y, Naini BV, Heard AN, Kim S, Capri J, Cohn W, Whitelegge JP, Vagin O
American journal of physiology. Gastrointestinal and liver physiology 2020 May 1;318(5):G931-G945
American journal of physiology. Gastrointestinal and liver physiology 2020 May 1;318(5):G931-G945
Proteomic Profile of Sorafenib Resistance in Hepatocellular Carcinoma; GRP78 Expression Is Associated With Inferior Response to Sorafenib.
Feng YH, Tung CL, Su YC, Tsao CJ, Wu TF
Cancer genomics & proteomics 2019 Nov-Dec;16(6):569-576
Cancer genomics & proteomics 2019 Nov-Dec;16(6):569-576
Differential effect of parity on rat mammary carcinogenesis after pre- or post-pubertal exposure to radiation.
Takabatake M, Daino K, Imaoka T, Blyth BJ, Kokubo T, Nishimura Y, Showler K, Hosoki A, Moriyama H, Nishimura M, Kakinuma S, Fukushi M, Shimada Y
Scientific reports 2018 Sep 25;8(1):14325
Scientific reports 2018 Sep 25;8(1):14325
Robust Bayesian Fluorescence Lifetime Estimation, Decay Model Selection and Instrument Response Determination for Low-Intensity FLIM Imaging.
Rowley MI, Coolen AC, Vojnovic B, Barber PR
PloS one 2016;11(6):e0158404
PloS one 2016;11(6):e0158404
Activating ERBB4 mutations in non-small cell lung cancer.
Kurppa KJ, Denessiouk K, Johnson MS, Elenius K
Oncogene 2016 Mar 10;35(10):1283-91
Oncogene 2016 Mar 10;35(10):1283-91
Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma.
El-Gendi SM, Mostafa MF
Pathology oncology research : POR 2016 Jul;22(3):461-70
Pathology oncology research : POR 2016 Jul;22(3):461-70
HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.
Weitsman G, Barber PR, Nguyen LK, Lawler K, Patel G, Woodman N, Kelleher MT, Pinder SE, Rowley M, Ellis PA, Purushotham AD, Coolen AC, Kholodenko BN, Vojnovic B, Gillett C, Ng T
Oncotarget 2016 Aug 9;7(32):51012-51026
Oncotarget 2016 Aug 9;7(32):51012-51026
A genetic basis for the variation in the vulnerability of cancer to DNA damage.
Yard BD, Adams DJ, Chie EK, Tamayo P, Battaglia JS, Gopal P, Rogacki K, Pearson BE, Phillips J, Raymond DP, Pennell NA, Almeida F, Cheah JH, Clemons PA, Shamji A, Peacock CD, Schreiber SL, Hammerman PS, Abazeed ME
Nature communications 2016 Apr 25;7:11428
Nature communications 2016 Apr 25;7:11428
Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.
Prince TL, Kijima T, Tatokoro M, Lee S, Tsutsumi S, Yim K, Rivas C, Alarcon S, Schwartz H, Khamit-Kush K, Scroggins BT, Beebe K, Trepel JB, Neckers L
PloS one 2015;10(10):e0141786
PloS one 2015;10(10):e0141786
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells.
Kan S, Koido S, Okamoto M, Hayashi K, Ito M, Kamata Y, Komita H, Nagasaki E, Homma S
BMC cancer 2015 Oct 16;15:726
BMC cancer 2015 Oct 16;15:726
Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.
Siegfried JM, Lin Y, Diergaarde B, Lin HM, Dacic S, Pennathur A, Weissfeld JL, Romkes M, Nukui T, Stabile LP
Neoplasia (New York, N.Y.) 2015 Nov;17(11):817-25
Neoplasia (New York, N.Y.) 2015 Nov;17(11):817-25
Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.
Gumusay O, Benekli M, Ekinci O, Baykara M, Ozet A, Coskun U, Demirci U, Uner A, Dursun A, Atak EY, Buyukberber S
Japanese journal of clinical oncology 2015 May;45(5):416-21
Japanese journal of clinical oncology 2015 May;45(5):416-21
Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine.
Kan S, Koido S, Okamoto M, Hayashi K, Ito M, Kamata Y, Komita H, Ishidao T, Nagasaki E, Homma S
Oncology reports 2015 Jul;34(1):504-10
Oncology reports 2015 Jul;34(1):504-10
The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines.
Abdel-Latif GA, Al-Abd AM, Tadros MG, Al-Abbasi FA, Khalifa AE, Abdel-Naim AB
Scientific reports 2015 Jul 9;5:12054
Scientific reports 2015 Jul 9;5:12054
Molecular architecture of the ErbB2 extracellular domain homodimer.
Hu S, Sun Y, Meng Y, Wang X, Yang W, Fu W, Guo H, Qian W, Hou S, Li B, Rao Z, Lou Z, Guo Y
Oncotarget 2015 Jan 30;6(3):1695-706
Oncotarget 2015 Jan 30;6(3):1695-706
Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
Asp N, Pust S, Sandvig K
Biochimica et biophysica acta 2014 Sep;1843(9):1987-96
Biochimica et biophysica acta 2014 Sep;1843(9):1987-96
Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas.
Boin A, Couvelard A, Couderc C, Brito I, Filipescu D, Kalamarides M, Bedossa P, De Koning L, Danelsky C, Dubois T, Hupé P, Louvard D, Lallemand D
Neuro-oncology 2014 Sep;16(9):1196-209
Neuro-oncology 2014 Sep;16(9):1196-209
Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers.
Brouxhon SM, Kyrkanides S, Teng X, O'Banion MK, Clarke R, Byers S, Ma L
Molecular carcinogenesis 2014 Nov;53(11):893-906
Molecular carcinogenesis 2014 Nov;53(11):893-906
HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.
Buza N, Roque DM, Santin AD
Archives of pathology & laboratory medicine 2014 Mar;138(3):343-50
Archives of pathology & laboratory medicine 2014 Mar;138(3):343-50
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.
Kirkegaard T, Hansen SK, Larsen SL, Reiter BE, Sørensen BS, Lykkesfeldt AE
Cancer letters 2014 Mar 1;344(1):90-100
Cancer letters 2014 Mar 1;344(1):90-100
Neuregulin-1/glial growth factor stimulates Schwann cell migration by inducing α5 β1 integrin-ErbB2-focal adhesion kinase complex formation.
Wakatsuki S, Araki T, Sehara-Fujisawa A
Genes to cells : devoted to molecular & cellular mechanisms 2014 Jan;19(1):66-77
Genes to cells : devoted to molecular & cellular mechanisms 2014 Jan;19(1):66-77
Hormone receptors and age distribution in breast cancer patients at a university hospital in northern egypt.
Hussein O, Mosbah M, Farouk O, Farag K, El-Saed A, Arafa M, Abdallah A
Breast cancer : basic and clinical research 2013;7:51-7
Breast cancer : basic and clinical research 2013;7:51-7
A cell-based screening system for influenza A viral RNA transcription/replication inhibitors.
Ozawa M, Shimojima M, Goto H, Watanabe S, Hatta Y, Kiso M, Furuta Y, Horimoto T, Peters NR, Hoffmann FM, Kawaoka Y
Scientific reports 2013;3:1106
Scientific reports 2013;3:1106
Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.
Grivas PD, Day KC, Karatsinides A, Paul A, Shakir N, Owainati I, Liebert M, Kunju LP, Thomas D, Hussain M, Day ML
Molecular medicine (Cambridge, Mass.) 2013 Nov 8;19(1):367-76
Molecular medicine (Cambridge, Mass.) 2013 Nov 8;19(1):367-76
Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2013 Jun;54(6):936-43
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2013 Jun;54(6):936-43
HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma.
Liu T, Sun B, Zhao X, Gu Q, Dong X, Yao Z, Zhao N, Chi J, Liu N, Sun R, Ma Y
Journal of cellular and molecular medicine 2013 Jan;17(1):116-22
Journal of cellular and molecular medicine 2013 Jan;17(1):116-22
Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
Scheer JM, Sandoval W, Elliott JM, Shao L, Luis E, Lewin-Koh SC, Schaefer G, Vandlen R
PloS one 2012;7(12):e51817
PloS one 2012;7(12):e51817
Association of human epidermal growth factor receptor-2 expression and clinicopathological findings in patients with colorectal cancer.
Karaca H, Deniz K, Berk V, Inanc M, Ozkan M
Asian Pacific journal of cancer prevention : APJCP 2012;13(12):6221-5
Asian Pacific journal of cancer prevention : APJCP 2012;13(12):6221-5
Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes.
Cheol Kim D, Thorat MA, Lee MR, Cho SH, Vasiljević N, Scibior-Bentkowska D, Wu K, Ahmad AS, Duffy S, Cuzick JM, Lorincz AT
Cancer biomarkers : section A of Disease markers 2012;11(2-3):75-88
Cancer biomarkers : section A of Disease markers 2012;11(2-3):75-88
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.
Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M
Annals of oncology : official journal of the European Society for Medical Oncology 2012 May;23(5):1144-1150
Annals of oncology : official journal of the European Society for Medical Oncology 2012 May;23(5):1144-1150
Clinicopathologic features of the mixed epithelial and mesenchymal type metaplastic breast carcinoma with myoepithelial differentiation in a subset of six cases.
Yigit S, Pehlivan FS, Evcim G, Etit D
Pathology, research and practice 2012 Mar 15;208(3):147-50
Pathology, research and practice 2012 Mar 15;208(3):147-50
EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway.
Cortés MA, Cariaga-Martinez AE, Lobo MV, Martín Orozco RM, Motiño O, Rodríguez-Ubreva FJ, Angulo J, López-Ruiz P, Colás B
Carcinogenesis 2012 Jun;33(6):1169-77
Carcinogenesis 2012 Jun;33(6):1169-77
Prognostic value of oncoprotein expressions in thyroid papillary carcinoma.
Balta AZ, Filiz AI, Kurt Y, Sucullu I, Yucel E, Akin ML
Medical oncology (Northwood, London, England) 2012 Jun;29(2):734-41
Medical oncology (Northwood, London, England) 2012 Jun;29(2):734-41
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF, Polydorides AD
Archives of pathology & laboratory medicine 2012 Jun;136(6):691-7
Archives of pathology & laboratory medicine 2012 Jun;136(6):691-7
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Jul 20;30(21):2601-8
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Jul 20;30(21):2601-8
Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs.
Henjes F, Bender C, von der Heyde S, Braun L, Mannsperger HA, Schmidt C, Wiemann S, Hasmann M, Aulmann S, Beissbarth T, Korf U
Oncogenesis 2012 Jul 2;1(7):e16
Oncogenesis 2012 Jul 2;1(7):e16
Early changes in carcinogenesis of colorectal adenomas.
Toru S, Bilezikçi B
The West Indian medical journal 2012 Jan;61(1):10-6
The West Indian medical journal 2012 Jan;61(1):10-6
Early changes in carcinogenesis of colorectal adenomas.
Toru S, Bilezikçi B
The West Indian medical journal 2012 Jan;61(1):10-6
The West Indian medical journal 2012 Jan;61(1):10-6
C-Erb-b2 oncogene expression in intraductal proliferative lesions of the breast.
Eren F, Calay Z, Durak H, Eren B, Comunoğlu N, Aydin O
Bosnian journal of basic medical sciences 2012 Feb;12(1):41-50
Bosnian journal of basic medical sciences 2012 Feb;12(1):41-50
Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype.
Jiang J, Zhang Y, Chuai S, Wang Z, Zheng D, Xu F, Zhang Y, Li C, Liang Y, Chen Z
Oncogene 2012 Feb 9;31(6):671-82
Oncogene 2012 Feb 9;31(6):671-82
ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells.
Krech T, Scheuerer E, Geffers R, Kreipe H, Lehmann U, Christgen M
Cancer letters 2012 Feb 28;315(2):153-60
Cancer letters 2012 Feb 28;315(2):153-60
Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model.
van de Ven SM, Elias SG, Chan CT, Miao Z, Cheng Z, De A, Gambhir SS
Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Feb 15;18(4):1073-81
Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Feb 15;18(4):1073-81
An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch.
Jahn SC, Law ME, Corsino PE, Parker NN, Pham K, Davis BJ, Lu J, Law BK
Cancer letters 2012 Dec 30;326(2):183-90
Cancer letters 2012 Dec 30;326(2):183-90
HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.
Duru N, Fan M, Candas D, Menaa C, Liu HC, Nantajit D, Wen Y, Xiao K, Eldridge A, Chromy BA, Li S, Spitz DR, Lam KS, Wicha MS, Li JJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Dec 15;18(24):6634-47
Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Dec 15;18(24):6634-47
Invasive lobular carcinoma with extracellular mucin as a distinct variant of lobular carcinoma: a case report.
Haltas H, Bayrak R, Yenidunya S, Kosehan D, Sen M, Akin K
Diagnostic pathology 2012 Aug 6;7:91
Diagnostic pathology 2012 Aug 6;7:91
Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome.
El-Gendi SM, Mostafa MF, El-Gendi AM
Pathology oncology research : POR 2012 Apr;18(2):459-69
Pathology oncology research : POR 2012 Apr;18(2):459-69
A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters.
Berta GN, Sprio AE, Iezzi M, Spadaro M, Cappia S, Salamone P, Di Scipio F, Mognetti B, Papotti M, Musiani P, Forni G, Cavallo F
Cancer prevention research (Philadelphia, Pa.) 2011 Jul;4(7):994-1001
Cancer prevention research (Philadelphia, Pa.) 2011 Jul;4(7):994-1001
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression.
Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G, Johansson H, Lindström L, Bergh J
Breast cancer research and treatment 2011 Jan;125(2):553-61
Breast cancer research and treatment 2011 Jan;125(2):553-61
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.
Bachleitner-Hofmann T, Sun MY, Chen CT, Liska D, Zeng Z, Viale A, Olshen AB, Mittlboeck M, Christensen JG, Rosen N, Solit DB, Weiser MR
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Jan 1;17(1):122-33
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Jan 1;17(1):122-33
Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Abdelzaher E, El-Gendi SM, Yehya A, Gowil AG
British journal of neurosurgery 2011 Dec;25(6):707-13
British journal of neurosurgery 2011 Dec;25(6):707-13
Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.
Rygiel AM, Milano F, Ten Kate FJ, Bergman JJ, Krishnadath KK
Journal of oncology 2010;2010:382582
Journal of oncology 2010;2010:382582
Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity.
Kozloski GA, Carraway CA, Carraway KL
Journal of cellular physiology 2010 Sep;224(3):649-57
Journal of cellular physiology 2010 Sep;224(3):649-57
HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.
Bollig-Fischer A, Dziubinski M, Boyer A, Haddad R, Giroux CN, Ethier SP
Cancer research 2010 Oct 15;70(20):7862-73
Cancer research 2010 Oct 15;70(20):7862-73
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R
Journal of translational medicine 2010 Jun 7;8:53
Journal of translational medicine 2010 Jun 7;8:53
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S, Lucci A
Cancer 2010 Jul 15;116(14):3330-7
Cancer 2010 Jul 15;116(14):3330-7
Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2/neu)-targeted immunotoxin with a replication-competent adenovirus or etoposide.
Liu X, Li J, Tian Y, Xu P, Chen X, Xie K, Qiu Z, Wang Y, Zhang D, Wolf F, Li C, Huang Q
Human gene therapy 2010 Feb;21(2):157-70
Human gene therapy 2010 Feb;21(2):157-70
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.
Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, Whitcomb J, Lingle W, Jenkins RB, Chen B, Larson JS, Tan Y, Sherwood T, Bates M, Perez EA
American journal of clinical pathology 2010 Aug;134(2):303-11
American journal of clinical pathology 2010 Aug;134(2):303-11
Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery.
Milano F, Guarriera M, Rygiel AM, Krishnadath KK
PloS one 2010 Aug 26;5(8):e12424
PloS one 2010 Aug 26;5(8):e12424
Immunohistochemical characterization of subtypes of male breast carcinoma.
Ge Y, Sneige N, Eltorky MA, Wang Z, Lin E, Gong Y, Guo M
Breast cancer research : BCR 2009;11(3):R28
Breast cancer research : BCR 2009;11(3):R28
HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats.
Misirlioglu D, Nak D, Ozyigit MO, Nak Y, Akkoc A
Journal of feline medicine and surgery 2009 Oct;11(10):885-8
Journal of feline medicine and surgery 2009 Oct;11(10):885-8
Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.
Gilcrease MZ, Woodward WA, Nicolas MM, Corley LJ, Fuller GN, Esteva FJ, Tucker SL, Buchholz TA
The American journal of surgical pathology 2009 May;33(5):759-67
The American journal of surgical pathology 2009 May;33(5):759-67
Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
Middleton LP, Price KM, Puig P, Heydon LJ, Tarco E, Sneige N, Barr K, Deavers MT
Archives of pathology & laboratory medicine 2009 May;133(5):775-80
Archives of pathology & laboratory medicine 2009 May;133(5):775-80
A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, Mukherjee A, Sperinde J, Pannu H, Chenna A, DeFazio-Eli L, Pidaparthi S, Badal Y, Wallweber G, Chen L, Williams S, Tahir H, Larson J, Goodman L, Whitcomb J, Petropoulos C, Winslow J
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2009 Mar;18(1):11-21
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2009 Mar;18(1):11-21
Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice.
Strumane K, Rygiel T, van der Valk M, Collard JG
Journal of cancer research and clinical oncology 2009 Jan;135(1):69-80
Journal of cancer research and clinical oncology 2009 Jan;135(1):69-80
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.
Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AM
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Jan 10;27(2):220-6
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Jan 10;27(2):220-6
Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F, Lampin A, Niwa-Kawakita M, Kalamarides M, Giovannini M
Oncogene 2009 Feb 12;28(6):854-65
Oncogene 2009 Feb 12;28(6):854-65
Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.
Gong Y, Sweet W, Duh YJ, Greenfield L, Tarco E, Trivedi S, Symmans WF, Isola J, Sneige N
American journal of clinical pathology 2009 Aug;132(2):228-36
American journal of clinical pathology 2009 Aug;132(2):228-36
Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression.
Kaya H, Bozkurt SU, Erbarut I, Djamgoz MB
Pathology, research and practice 2008;204(6):367-71
Pathology, research and practice 2008;204(6):367-71
Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent.
Pedersen NM, Madshus IH, Haslekås C, Stang E
Molecular cancer research : MCR 2008 Mar;6(3):491-500
Molecular cancer research : MCR 2008 Mar;6(3):491-500
Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.
Bao H, Yu D, Wang J, Qiu T, Yang J, Wang L
Anti-cancer drugs 2008 Mar;19(3):317-23
Anti-cancer drugs 2008 Mar;19(3):317-23
Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.
Bao H, Yu D, Wang J, Qiu T, Yang J, Wang L
Anti-cancer drugs 2008 Mar;19(3):317-23
Anti-cancer drugs 2008 Mar;19(3):317-23
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L
Breast cancer research and treatment 2008 Mar;108(2):183-90
Breast cancer research and treatment 2008 Mar;108(2):183-90
The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation.
Najy AJ, Day KC, Day ML
The Journal of biological chemistry 2008 Jun 27;283(26):18393-401
The Journal of biological chemistry 2008 Jun 27;283(26):18393-401
Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes.
Cai Z, Zhang G, Zhou Z, Bembas K, Drebin JA, Greene MI, Zhang H
Oncogene 2008 Jun 19;27(27):3870-4
Oncogene 2008 Jun 19;27(27):3870-4
Lipid raft localization of ErbB2 in vestibular schwannoma and schwann cells.
Brown KD, Hansen MR
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2008 Jan;29(1):79-85
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2008 Jan;29(1):79-85
Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer.
Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, Adam L, Wei C, Baggerly K, Bar-Eli M, McConkey D, Czerniak B, Dinney CP
The Journal of urology 2008 Jan;179(1):353-8
The Journal of urology 2008 Jan;179(1):353-8
Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Hu S, Zhu Z, Li L, Chang L, Li W, Cheng L, Teng M, Liu J
Proteins 2008 Feb 15;70(3):938-49
Proteins 2008 Feb 15;70(3):938-49
Loss of annexin A1 expression in breast cancer progression.
Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT
Applied immunohistochemistry & molecular morphology : AIMM 2008 Dec;16(6):530-4
Applied immunohistochemistry & molecular morphology : AIMM 2008 Dec;16(6):530-4
A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents.
Piechocki MP
BMC cancer 2008 Apr 24;8:119
BMC cancer 2008 Apr 24;8:119
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ
Breast cancer research : BCR 2007;9(5):R65
Breast cancer research : BCR 2007;9(5):R65
Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF.
Kiley SC, Chevalier RL
American journal of physiology. Renal physiology 2007 Sep;293(3):F895-903
American journal of physiology. Renal physiology 2007 Sep;293(3):F895-903
Primary neuroendocrine carcinoma of the breast: a case report.
Yaren A, Kelten C, Akbulut M, Teke Z, Duzcan E, Erdem E
Tumori 2007 Sep-Oct;93(5):496-8
Tumori 2007 Sep-Oct;93(5):496-8
Primary neuroendocrine carcinoma of the breast: a case report.
Yaren A, Kelten C, Akbulut M, Teke Z, Duzcan E, Erdem E
Tumori 2007 Sep-Oct;93(5):496-8
Tumori 2007 Sep-Oct;93(5):496-8
Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Ostrander JH, Daniel AR, Lofgren K, Kleer CG, Lange CA
Cancer research 2007 May 1;67(9):4199-209
Cancer research 2007 May 1;67(9):4199-209
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.
Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF
The Lancet. Oncology 2007 Mar;8(3):203-11
The Lancet. Oncology 2007 Mar;8(3):203-11
The ErbB4 receptor in fetal rat lung fibroblasts and epithelial type II cells.
Liu W, Zscheppang K, Murray S, Nielsen HC, Dammann CE
Biochimica et biophysica acta 2007 Jul;1772(7):737-47
Biochimica et biophysica acta 2007 Jul;1772(7):737-47
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van't Veer LJ
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Jan 1;25(1):64-9
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Jan 1;25(1):64-9
Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
Schaefer G, Shao L, Totpal K, Akita RW
Cancer research 2007 Feb 1;67(3):1228-38
Cancer research 2007 Feb 1;67(3):1228-38
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M
Cancer 2007 Feb 1;109(3):496-501
Cancer 2007 Feb 1;109(3):496-501
ErbB4 regulates fetal surfactant phospholipid synthesis in primary fetal rat type II cells.
Zscheppang K, Liu W, Volpe MV, Nielsen HC, Dammann CE
American journal of physiology. Lung cellular and molecular physiology 2007 Aug;293(2):L429-35
American journal of physiology. Lung cellular and molecular physiology 2007 Aug;293(2):L429-35
Abundance and localization of skeletal muscle-related erbB2 may stimulate tumour growth during initial stages of oral oncogenesis.
Vairaktaris E, Moulavassili P, Loukeri S, Spyridonidou S, Yapijakis C, Vassiliou S, Nkenke E, Vylliotis A, Papakosta V, Lazaris A, Patsouris E
Journal of musculoskeletal & neuronal interactions 2007 Apr-Jun;7(2):185-90
Journal of musculoskeletal & neuronal interactions 2007 Apr-Jun;7(2):185-90
[An analysis of genetic transmission in a father and son with osteosarcoma].
Tokatli F, Alas RC, Altaner S, Pala F, Uygun K, Uzal C, Yalniz E
Acta orthopaedica et traumatologica turcica 2006;40(5):407-10
Acta orthopaedica et traumatologica turcica 2006;40(5):407-10
MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC).
Karg A, Dinç ZA, Başok O, Uçvet A
Pathology, research and practice 2006;202(8):577-83
Pathology, research and practice 2006;202(8):577-83
Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way.
Lerdrup M, Hommelgaard AM, Grandal M, van Deurs B
Journal of cell science 2006 Jan 1;119(Pt 1):85-95
Journal of cell science 2006 Jan 1;119(Pt 1):85-95
ErbB receptor dimerization, localization, and co-localization in mouse lung type II epithelial cells.
Zscheppang K, Korenbaum E, Bueter W, Ramadurai SM, Nielsen HC, Dammann CE
Pediatric pulmonology 2006 Dec;41(12):1205-12
Pediatric pulmonology 2006 Dec;41(12):1205-12
Clonal nature of sclerosing polycystic adenosis of salivary glands demonstrated by using the polymorphism of the human androgen receptor (HUMARA) locus as a marker.
Skálová A, Gnepp DR, Simpson RH, Lewis JE, Janssen D, Sima R, Vanecek T, Di Palma S, Michal M
The American journal of surgical pathology 2006 Aug;30(8):939-44
The American journal of surgical pathology 2006 Aug;30(8):939-44
Clonal nature of sclerosing polycystic adenosis of salivary glands demonstrated by using the polymorphism of the human androgen receptor (HUMARA) locus as a marker.
Skálová A, Gnepp DR, Simpson RH, Lewis JE, Janssen D, Sima R, Vanecek T, Di Palma S, Michal M
The American journal of surgical pathology 2006 Aug;30(8):939-44
The American journal of surgical pathology 2006 Aug;30(8):939-44
Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation.
Hansen MR, Roehm PC, Chatterjee P, Green SH
Glia 2006 Apr 15;53(6):593-600
Glia 2006 Apr 15;53(6):593-600
Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.
Cabioglu N, Sahin A, Doucet M, Yavuz E, Igci A, O Yildirim E, Aktas E, Bilgic S, Kiran B, Deniz G, Price JE
Clinical & experimental metastasis 2005;22(1):39-46
Clinical & experimental metastasis 2005;22(1):39-46
The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Gao RJ, Bao HZ, Yang Q, Cong Q, Song JN, Wang L
Breast cancer research and treatment 2005 Sep;93(2):111-5
Breast cancer research and treatment 2005 Sep;93(2):111-5
Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer.
Diaz LK, Cristofanilli M, Zhou X, Welch KL, Smith TL, Yang Y, Sneige N, Sahin AA, Gilcrease MZ
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005 Sep;18(9):1165-75
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005 Sep;18(9):1165-75
Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells.
Stewart LV, Lyles B, Lin MF, Weigel NL
The Journal of steroid biochemistry and molecular biology 2005 Oct;97(1-2):37-46
The Journal of steroid biochemistry and molecular biology 2005 Oct;97(1-2):37-46
Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer.
Khalili P, Arakelian A, Chen G, Singh G, Rabbani SA
Oncogene 2005 Oct 6;24(44):6657-66
Oncogene 2005 Oct 6;24(44):6657-66
CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 May 1;11(9):3309-14
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 May 1;11(9):3309-14
Cystic hypersecretory carcinoma: rare and poorly recognized variant of intraductal carcinoma of the breast. Report of five cases.
Skalova A, Ryska A, Kajo K, Di Palma S, Kinkor Z, Michal M
Histopathology 2005 Jan;46(1):43-9
Histopathology 2005 Jan;46(1):43-9
Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry.
Di Palma S, Skálová A, Vanìèek T, Simpson RH, Stárek I, Leivo I
Histopathology 2005 Feb;46(2):144-52
Histopathology 2005 Feb;46(2):144-52
Concordant loss of fragile gene expression early in breast cancer development.
Guler G, Uner A, Guler N, Han SY, Iliopoulos D, McCue P, Huebner K
Pathology international 2005 Aug;55(8):471-8
Pathology international 2005 Aug;55(8):471-8
Effect of N-cadherin misexpression by the mammary epithelium in mice.
Knudsen KA, Sauer C, Johnson KR, Wheelock MJ
Journal of cellular biochemistry 2005 Aug 15;95(6):1093-107
Journal of cellular biochemistry 2005 Aug 15;95(6):1093-107
Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy.
Price-Schiavi SA, Andrechek E, Idris N, Li P, Rong M, Zhang J, Carothers Carraway CA, Muller WJ, Carraway KL
Journal of cellular physiology 2005 Apr;203(1):44-53
Journal of cellular physiology 2005 Apr;203(1):44-53
Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK.
Kansra S, Stoll SW, Johnson JL, Elder JT
Molecular biology of the cell 2004 Sep;15(9):4299-309
Molecular biology of the cell 2004 Sep;15(9):4299-309
Ductal carcinoma in situ with spindle cells: a potential diagnostic pitfall in the evaluation of breast lesions.
Tan PH, Lui GG, Chiang G, Yap WM, Poh WT, Bay BH
Histopathology 2004 Oct;45(4):343-51
Histopathology 2004 Oct;45(4):343-51
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP
Gynecologic oncology 2004 Jan;92(1):160-6
Gynecologic oncology 2004 Jan;92(1):160-6
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP
Gynecologic oncology 2004 Jan;92(1):160-6
Gynecologic oncology 2004 Jan;92(1):160-6
Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients.
Gossett DR, Alo P, Bristow RE, Galati M, Kyshtoobayeva A, Fruehauf J, Montz FJ
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004 Jan-Feb;14(1):145-51
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004 Jan-Feb;14(1):145-51
Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients.
Gossett DR, Alo P, Bristow RE, Galati M, Kyshtoobayeva A, Fruehauf J, Montz FJ
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004 Jan-Feb;14(1):145-51
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004 Jan-Feb;14(1):145-51
Role of ErbB2 in Corneal Epithelial Wound Healing.
Xu KP, Riggs A, Ding Y, Yu FS
Investigative ophthalmology & visual science 2004 Dec;45(12):4277-83
Investigative ophthalmology & visual science 2004 Dec;45(12):4277-83
Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
Zinser GM, Welsh J
Carcinogenesis 2004 Dec;25(12):2361-72
Carcinogenesis 2004 Dec;25(12):2361-72
Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A
Cancer 2003 Sep 1;98(5):1055-60
Cancer 2003 Sep 1;98(5):1055-60
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Nov 15;9(15):5652-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Nov 15;9(15):5652-9
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
Vadlamudi RK, Sahin AA, Adam L, Wang RA, Kumar R
FEBS letters 2003 May 22;543(1-3):76-80
FEBS letters 2003 May 22;543(1-3):76-80
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
Vadlamudi RK, Sahin AA, Adam L, Wang RA, Kumar R
FEBS letters 2003 May 22;543(1-3):76-80
FEBS letters 2003 May 22;543(1-3):76-80
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.
Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Mar;9(3):955-60
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Mar;9(3):955-60
Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells.
Thomas CY, Chouinard M, Cox M, Parsons S, Stallings-Mann M, Garcia R, Jove R, Wharen R
International journal of cancer 2003 Mar 10;104(1):19-27
International journal of cancer 2003 Mar 10;104(1):19-27
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.
Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC Jr, Kudelka AP, Kavanagh JJ, Giovanella BC
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Feb;9(2):845-52
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Feb;9(2):845-52
Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
Shimizu H, Seiki T, Asada M, Yoshimatsu K, Koyama N
Oncogene 2003 Feb 13;22(6):831-9
Oncogene 2003 Feb 13;22(6):831-9
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Simpson RH, Prasad AR, Lewis JE, Skálová A, David L
The American journal of surgical pathology 2003 Aug;27(8):1070-9
The American journal of surgical pathology 2003 Aug;27(8):1070-9
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Simpson RH, Prasad AR, Lewis JE, Skálová A, David L
The American journal of surgical pathology 2003 Aug;27(8):1070-9
The American journal of surgical pathology 2003 Aug;27(8):1070-9
Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells.
Ramsauer VP, Carraway CA, Salas PJ, Carraway KL
The Journal of biological chemistry 2003 Aug 8;278(32):30142-7
The Journal of biological chemistry 2003 Aug 8;278(32):30142-7
Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease.
Kremser R, Obrist P, Spizzo G, Erler H, Kendler D, Kemmler G, Mikuz G, Ensinger C
Virchows Archiv : an international journal of pathology 2003 Apr;442(4):322-8
Virchows Archiv : an international journal of pathology 2003 Apr;442(4):322-8
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT
Journal of immunology (Baltimore, Md. : 1950) 2003 Apr 15;170(8):4242-53
Journal of immunology (Baltimore, Md. : 1950) 2003 Apr 15;170(8):4242-53
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT
Journal of immunology (Baltimore, Md. : 1950) 2003 Apr 15;170(8):4242-53
Journal of immunology (Baltimore, Md. : 1950) 2003 Apr 15;170(8):4242-53
Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer.
Tsigris C, Karayiannakis AJ, Zbar A, Syrigos KN, Baibas N, Diamantis T, Alexiou D
Cancer letters 2002 Oct 28;184(2):215-22
Cancer letters 2002 Oct 28;184(2):215-22
Classification of low-grade neuroendocrine tumors of midgut and unknown origin.
Van Eeden S, Quaedvlieg PF, Taal BG, Offerhaus GJ, Lamers CB, Van Velthuysen ML
Human pathology 2002 Nov;33(11):1126-32
Human pathology 2002 Nov;33(11):1126-32
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA
Cancer research 2002 Mar 15;62(6):1676-81
Cancer research 2002 Mar 15;62(6):1676-81
Differential cytoskeletal association of ErbB1 and ErbB2 during keratinocyte differentiation.
Kansra S, Stoll SW, Elder JT
Biochemical and biophysical research communications 2002 Aug 2;295(5):1108-17
Biochemical and biophysical research communications 2002 Aug 2;295(5):1108-17
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 Apr 1;20(7):1800-8
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 Apr 1;20(7):1800-8
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 Apr 1;20(7):1800-8
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 Apr 1;20(7):1800-8
Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
Murillo H, Schmidt LJ, Tindall DJ
Cancer research 2001 Oct 15;61(20):7408-12
Cancer research 2001 Oct 15;61(20):7408-12
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Moasser MM, Basso A, Averbuch SD, Rosen N
Cancer research 2001 Oct 1;61(19):7184-8
Cancer research 2001 Oct 1;61(19):7184-8
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot of HER-2 using HER-2 Monoclonal Antibody (Product # MA5-14057) on LS174T Cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis was performed on membrane enriched extracts (30 µg lysate) of SK-BR-3 (1), T-47D (2) and MDA-MB-231 (3). The blot was probed with anti-ErbB2 Mouse Monoclonal Antibody (Product # MA5-14057, 1 µg/mL) and detected by chemiluminescence using Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A28177, 0.25 µg/mL, 1:4000 dilution). A 185 kDa band corresponding to ErbB2 was observed in SK-BR-3 and moderate in T-47D where as it was not observed in MDA-MB-231 which is an ErbB2 negative cell line. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 4-12 % Bis-Tris gel (Product # NP0321BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane using the wet transfer system. The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of ERBB2 was performed with 10 µg of A549 cells transfected with Transfection Reagent alone (Lane 1), 100nM Non-Targeting control siRNA (Lane 2), or 100nM siRNA against ERBB2 (Lane 3). Proteins were resolved using a NuPAGE® Novex 4-12% Bis-Tris Gel (Product # NP0322BOX), XCell SureLock™ Electrophoresis System (Product # EI0002), and a protein size ladder. Proteins were wet transferred to a Pierce Nitrocellulose Membrane (Product # 88025) OR Pierce PVDF Membrane (Product # 88518) and blocked with Pierce Starting Block T20 (PBS) Blocking Buffer (Product # 37539) for 1 hour at room temperature. ERBB2 was detected at ~ 185 kDa using ERBB2 Mouse monoclonal antibody (Product # MA5-14057) diluted in Pierce Starting Block T20 (PBS) Blocking Buffer 4°C overnight on a rocking platform. Pierce Goat Anti-Mouse (Product # 31437) HRP-Conjugated Antibodies at a 1:2500 dilution were used and chemiluminescent detection was performed using Pierce Supersignal West Dura Maximum Sensitivity Substrate (Product # 37071). Relative density of the bands normalized to GAPDH (36 kDa). ERBB2 Antibody (Product # MA5-14057) confirms silencing of ERBB2 expression.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis was performed on membrane enriched extracts (30 µg lysate) of SK-BR-3 (1), T-47D (2) and MDA-MB-231 (3). The blot was probed with anti-ErbB2 Mouse Monoclonal Antibody (Product # MA5-14057, 1 µg/mL) and detected by chemiluminescence using Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A28177, 0.25 µg/mL, 1:4000 dilution). A 185 kDa band corresponding to ErbB2 was observed in SK-BR-3 and moderate in T-47D where as it was not observed in MDA-MB-231 which is an ErbB2 negative cell line. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 4-12 % Bis-Tris gel (Product # NP0321BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane using the wet transfer system. The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Formalin-fixed, paraffin-embedded human breast carcinoma stained with c-erbB2 antibody7 using peroxidase-conjugate and DAB chromogen. Note cell membrane staining of tumor cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Formalin-fixed, paraffin-embedded human breast carcinoma stained with c-erbB2 antibody7 using peroxidase-conjugate and DAB chromogen. Note cell membrane staining of tumor cells.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of HER-2/ErbB2 in MDA-MB-453 cells (green) compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/mL, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with a HER-2/ErbB2 monoclonal antibody (Product # MA5-14057) at a dilution of 1:50 for 60 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated secondary antibody and re-suspended in PBS for FACS analysis.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of HER-2/ErbB2 in PC-12 cells (green) compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/mL, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with a HER-2/ErbB2 monoclonal antibody (Product # MA5-14057) at a dilution of 1:50 for 60 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated secondary antibody and re-suspended in PBS for FACS analysis.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of HER-2/ErbB2 in SK-BR-3 cells (green) compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/mL, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with a HER-2/ErbB2 monoclonal antibody (Product # MA5-14057) at a dilution of 1:50 for 60 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated secondary antibody and re-suspended in PBS for FACS analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5. KLF5 controls cell proliferation in OAC. ( A ) Heatmap of ATAC-seq signal at regions (peak centre +-2.5 kb) with significantly differential accessibility (+-2 x; Q < 0.05) in OE19 cells treated with siERBB2. ( B ) Bar chart of percentage targets and percentage background of de novo discovered motifs at regions closed with siERBB2 treatment in OE19 cells. De novo motifs, called transcription factor with motif match scores (brackets) and p-values are shown. ( C ) Tag density plot of ATAC-seq signal from BO and OAC tissue at regions that demonstrate KLF5 binding in OE19 cells and reduced chromatin accessibility in OE19 cells upon siERBB2 treatment. ( D ) Heatmap of z-score of expression of KLF5 direct target genes in OE19 cells treated with either siNT or siERBB2. Cell cycle related genes are indicated with a black bar. ( E ) Bar chart showing the % relative growth of OE19 cells treated with either siNT or siKLF5. p-Value is shown (n = 3). ( F ) Bar chart showing the % relative growth of OE19-dCas9-KRAB cells treated with either non-targeting guides or guides targeting the KLF5 TSS. p-Value is shown (n = 3). ( G ) Bar chart showing the % relative growth of OE19 cells treated with either siNT or siRNA against the indicated target genes. p-Values are shown (n = 3). ( H ) Kaplan-Meier curves of patient survival across 24 months for high (above median; red) or low (below median; blue) expression of the 97 KLF5 target genes (left), KLF5 (middle) or CLSPN (right). p-Values a
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Expression of ERBB-2 in PPGLs. (A) Weakly positive immunostaining of ERBB-2 in PPGLs. (B) Intermediately positive immunostaining of ERBB-2 in PPGLs. (C) Strongly positive immunostaining of ERBB-2 in PPGLs.